Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients diagnosed with lung cancer remains between 15 and 20%. Newer therapeutic strategies rely on specific molecular altera...

Descripción completa

Detalles Bibliográficos
Autores principales: Korpanty, Grzegorz J., Graham, Donna M., Vincent, Mark D., Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127527/
https://www.ncbi.nlm.nih.gov/pubmed/25157335
http://dx.doi.org/10.3389/fonc.2014.00204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127527/
https://www.ncbi.nlm.nih.gov/pubmed/25157335
http://dx.doi.org/10.3389/fonc.2014.00204

Ejemplares similares